ImmunityBio, Inc. (IBRX)
NASDAQ: IBRX · Real-Time Price · USD
2.020
+0.040 (2.02%)
At close: Jan 2, 2026, 4:00 PM EST
2.050
+0.030 (1.49%)
After-hours: Jan 2, 2026, 7:57 PM EST
ImmunityBio Revenue
ImmunityBio had revenue of $32.06M in the quarter ending September 30, 2025, with 425.07% growth. This brings the company's revenue in the last twelve months to $82.56M, up 1,025.95% year-over-year. In the year 2024, ImmunityBio had annual revenue of $14.75M with 2,270.58% growth.
Revenue (ttm)
$82.56M
Revenue Growth
+1,025.95%
P/S Ratio
20.94
Revenue / Employee
$121,404
Employees
680
Market Cap
1.99B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 14.75M | 14.12M | 2,270.58% |
| Dec 31, 2023 | 622.00K | 382.00K | 159.17% |
| Dec 31, 2022 | 240.00K | -694.00K | -74.30% |
| Dec 31, 2021 | 934.00K | 329.00K | 54.38% |
| Dec 31, 2020 | 605.00K | -1.60M | -72.52% |
| Dec 31, 2019 | 2.20M | 2.16M | 4,585.11% |
| Dec 31, 2018 | 47.00K | 2.00K | 4.44% |
| Dec 31, 2017 | 45.00K | 1,000.00 | 2.27% |
| Dec 31, 2016 | 44.00K | -192.00K | -81.36% |
| Dec 31, 2015 | 236.00K | -405.00K | -63.18% |
| Dec 31, 2014 | 641.00K | 41.00K | 6.83% |
| Dec 31, 2013 | 600.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
IBRX News
- 4 days ago - ImmunityBio Founder Dr. Patrick Soon-Shiong Recognized as One of “100 Most Influential People in Oncology in 2025” - Business Wire
- 17 days ago - ANKTIVA® with BCG Demonstrates 96% Survival from Bladder Cancer at Three Years with Median Survival Not Yet Reached in BCG-Unresponsive High-Grade Papillary-Only Non-Muscle Invasive Bladder Cancer - Business Wire
- 21 days ago - ImmunityBio Moves Closer To EU Approval For Bladder Cancer Therapy - Benzinga
- 21 days ago - ImmunityBio Receives Conditional Marketing Authorization Recommendation from the European Medicines Agency for ANKTIVA® with BCG for Non-Muscle Invasive Bladder Cancer Carcinoma in Situ—A First in Europe - Business Wire
- 4 weeks ago - A Second Anktiva Approval Could Be The Catalyst ImmunityBio Needs - Seeking Alpha
- 6 weeks ago - ImmunityBio: Checking The Boxes Of A True Commercial-Stage Biotech - Seeking Alpha
- 7 weeks ago - New Survey Reveals Non-Muscle Invasive Bladder Cancer Patients Seek More Care Conversations - Business Wire
- 2 months ago - Driven by Strong Demand, ImmunityBio Reports 467% Year-to-Date Unit Growth and $75 Million in Sales Year-to-Date, Up 434% from Q3 2024 - Business Wire